Adicet Bio, Inc. SEC 10-Q Report

Adicet Bio, Inc., a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has released its Form 10-Q report for the third quarter of 2025. The report provides a comprehensive overview of the company's financial performance and key business developments during the period.

Financial Highlights

Total Operating Expenses: $29.9 million, decreased by 3% compared to the same period in 2024, primarily due to a decrease in expenses related to CDMOs and other externally conducted research and development.

Loss from Operations: $(29.9) million, decreased by 3% compared to the same period in 2024.

Net Loss: $(28.2) million, increased by 1% compared to the same period in 2024.

Net Loss Per Share, Basic and Diluted: $(0.31), improved from $(0.35) in the same period in 2024.

Interest Income: $1.7 million, decreased by 42% compared to the same period in 2024, primarily due to lower interest rates and cash balances.

Business Highlights

Product Development: Adicet Bio is advancing its pipeline of allogeneic gamma delta T cell therapies, focusing on autoimmune diseases and cancer. The lead product candidate, ADI-001, targets CD20 for potential treatment of autoimmune diseases, while ADI-270 targets CD70 for renal cell carcinoma and other solid tumors.

Clinical Trials: The company has initiated a Phase 1 clinical trial for ADI-001 in autoimmune diseases, including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, and other conditions. ADI-270 is also in a Phase 1 trial for renal cell carcinoma, with preliminary data expected in the second half of 2025.

Regulatory Milestones: ADI-001 received Fast Track Designation from the FDA for lupus nephritis and systemic sclerosis, highlighting its potential in treating these conditions.

Operational Focus: The company is prioritizing the development of ADI-001 in autoimmune indications, which has led to the closure of patient enrollment in the Phase 1 study of ADI-001 for mantle cell lymphoma.

Future Outlook: Adicet Bio plans to file a new Investigational New Drug (IND) application every 12-18 months, aiming to expand its pipeline and address unmet medical needs in autoimmune diseases and cancer.

Research and Development Strategy: The company is leveraging its gamma delta T cell platform to develop product candidates using previously validated antigens and new targets identified through CAR and other technologies.

Geographical Expansion: Adicet Bio has initiated research and development activities in China through its subsidiary, Adicet Shanghai, to enhance its global research capabilities.

Strategic Initiatives: The company is focused on enhancing its operational systems and attracting key personnel to support the development and potential commercialization of its product candidates.

SEC Filing: Adicet Bio, Inc. [ ACET ] - 10-Q - May. 06, 2025